Tiny Ok­la­homa com­pa­ny gets the eye of Boehringer In­gel­heim, sign­ing deal for re­gen­er­a­tive hear­ing loss treat­ment

Rel­a­tive to things like on­col­o­gy and gene ther­a­py, the field of hear­ing loss is small in the biotech world. When look­ing at hear­ing loss and re­gen­er­a­tive med­i­cine to­geth­er, the space shrinks even fur­ther.

Now, the small, Ok­la­homa City-based Auti­gen is mak­ing its way in­to the ring — and look­ing to be the first biotech to fi­nal­ly crack re­gen­er­at­ing hair cells in the in­ner ear.

Auti­gen an­nounced a col­lab­o­ra­tion with the Boehringer In­gel­heim ear­ly Wednes­day to go af­ter SNHL, or sen­sorineur­al hear­ing loss. The com­pa­ny nabbed an undis­closed up­front pay­ment from Boehringer, along with an un­spec­i­fied amount for re­search sup­port and an un­spec­i­fied du­ra­tion of said col­lab­o­ra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER